These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34871070)

  • 1. Raising Medicaid Rebates For Drugs With Accelerated Approval.
    Rome BN; Kesselheim AS
    Health Aff (Millwood); 2021 Dec; 40(12):1935-1942. PubMed ID: 34871070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval.
    Sachs RE; Gavulic KA; Donohue JM; Dusetzina SB
    JAMA Health Forum; 2021 Oct; 2(10):e213177. PubMed ID: 35977163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20.
    Rome BN; Patel AN; Kesselheim AS
    Health Aff (Millwood); 2023 Jun; 42(6):770-778. PubMed ID: 37276474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
    Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits.
    Sachs RE; Jazowski SA; Gavulic KA; Donohue JM; Dusetzina SB
    J Health Polit Policy Law; 2022 Dec; 47(6):673-690. PubMed ID: 35867545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
    Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
    JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
    Neumann PJ; Crummer E; Chambers JD; Tunis SR
    Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicaid Spending on Antiretrovirals From 2007 Through 2019.
    Walsh BS; Kesselheim AS; Rome BN
    Clin Infect Dis; 2023 Mar; 76(5):833-841. PubMed ID: 36268585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
    Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
    JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reforming Reimbursement for the US Food and Drug Administration's Accelerated Approval Program to Support State Medicaid Programs.
    Sachs RE; Donohue JM; Dusetzina SB
    JAMA Health Forum; 2022 Nov; 3(11):e224115. PubMed ID: 36399351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.
    Naci H; Smalley KR; Kesselheim AS
    JAMA; 2017 Aug; 318(7):626-636. PubMed ID: 28810023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018.
    Omae K; Onishi A; Sahker E; Furukawa TA
    JAMA Netw Open; 2022 Sep; 5(9):e2230973. PubMed ID: 36083581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicare Spending on Drugs With Accelerated Approval.
    Ballreich J; Socal M; Bennett CL; Schoen MW; Trujillo A; Xuan A; Anderson G
    Ann Intern Med; 2022 Jul; 175(7):938-944. PubMed ID: 35605235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in Medicaid Rebates Paid by Pharmaceutical Manufacturers for Outpatient Infused, Injected, Implanted, Inhaled, or Instilled Drugs: The 5i Loophole.
    Dickson S; Gabriel N; Gellad W; Hernandez I
    J Health Polit Policy Law; 2022 Dec; 47(6):835-851. PubMed ID: 35867551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of 1990 Medicaid drug rebates policy on access to prescriptions.
    Okunade AA
    J Health Soc Policy; 2001; 12(3):33-51. PubMed ID: 11146982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating Rebates and Other Discounts Received by Medicare Part D.
    Feldman WB; Rome BN; Raimond VC; Gagne JJ; Kesselheim AS
    JAMA Health Forum; 2021 Jun; 2(6):e210626. PubMed ID: 36218748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
    Rome BN; Feldman WB; Desai RJ; Kesselheim AS
    JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.